RAS-mediated suppression of PAR3 and its effects on SCC initiation and tissue architecture occur independently of

Ji Ling1, Maria Sckaff1, Manisha Tiwari1

  • 1Department of Dermatology, Department of Cellular and Molecular Medicine, UCSD Stem Cell Program, University of California, San Diego, La Jolla, CA 92093-0869, USA.

Journal of Cell Science
|November 11, 2020
PubMed

Insights

RAS-dependent suppression of PAR3 accelerates squamous cell carcinoma (SCC) development by disrupting cell adhesion and division. MAPK pathway inhibition restored normal tissue architecture, identifying PAR3 as a key regulator in early SCC.

Area of Science:

  • Oncology
  • Cell Biology
  • Developmental Biology

Background:

  • Epithelial homeostasis relies on controlled cell division, influenced by polarity factors and spatial cues.
  • Investigating spindle orientation in human epithelial carcinoma has been limited by the absence of suitable skin models.

Purpose of the Study:

  • To investigate spindle orientation deregulation in human squamous cell carcinoma (SCC) using an inducible model.
  • To identify molecular mechanisms driving early epithelial disorganization in SCC.

Main Methods:

  • Development of an inducible human squamous cell carcinoma (SCC) model.
  • Analysis of PAR3 (PARD3) expression and its role in cell adhesion and spindle orientation.
  • Pharmacological inhibition of the MAPK pathway.

Main Results:

  • RAS-dependent suppression of PAR3 accelerates epithelial disorganization in early SCC.
  • Reduced PAR3 expression leads to loss of E-cadherin-mediated cell adhesion and misoriented cell division.
  • MAPK pathway inhibition reverses PAR3 suppression, adhesion defects, and spindle misorientation.

Conclusions:

  • PAR3 is a critical regulator of tissue architecture during initial human SCC development.
  • Temporal analysis of human neoplasia is a powerful approach for studying early oncogenesis.
  • Targeting the RAS-MAPK-PAR3 axis may offer therapeutic strategies for SCC.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.3K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
9.7K